| Added by | mollevi |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers |
| Creator | Ferrari et al. |
| Author | Anthony Ferrari |
| Author | Anne Vincent-Salomon |
| Author | Xavier Pivot |
| Author | Anne-Sophie Sertier |
| Author | Emilie Thomas |
| Author | Laurie Tonon |
| Author | Sandrine Boyault |
| Author | Eskeatnaf Mulugeta |
| Author | Isabelle Treilleux |
| Author | Laurent Arnould |
| Author | Janice Kielbassa |
| Author | Vincent Le Texier |
| Author | Hélène Blanché |
| Author | Jean-François Deleuze |
| Author | Jocelyne Jacquemier |
| Author | Marie-Christine Mathieu |
| Author | Frédérique Penault-Llorca |
| Author | Frédéric Bibeau |
| Author | Odette Mariani |
| Author | Cécile Mannina |
| Author | Jean-Yves Pierga |
| Author | Thomas Bachelot |
| Author | Hervé Bonnefoi |
| Author | Gilles Romieu |
| Author | Pierre Fumoleau |
| Author | Suzette Delaloge |
| Author | Maria Rios |
| Author | Jean-Marc Ferrero |
| Author | Carole Tarpin |
| Author | Catherine Bouteille |
| Author | Fabien Calvo |
| Author | Ivo Glynne Gut |
| Author | Marta Gut |
| Author | Sancha Martin |
| Author | Serena Nik-Zainal |
| Author | Michael R. Stratton |
| Author | Iris Pauporté |
| Author | Pierre Saintigny |
| Author | Daniel Birnbaum |
| Author | Alain Viari |
| Author | Gilles Thomas |
| Abstract | HER2-positive breast cancer has long proven to be a clinically distinct class of breast cancers for which several targeted therapies are now available. However, resistance to the treatment associated with specific gene expressions or mutations has been observed, revealing the underlying diversity of these cancers. Therefore, understanding the full extent of the HER2-positive disease heterogeneity still remains challenging. Here we carry out an in-depth genomic characterization of 64 HER2-positive breast tumour genomes that exhibit four subgroups, based on the expression data, with distinctive genomic features in terms of somatic mutations, copy-number changes or structural variations. The results suggest that, despite being clinically defined by a specific gene amplification, HER2-positive tumours melt into the whole luminal-basal breast cancer spectrum rather than standing apart. The results also lead to a refined ERBB2 amplicon of 106?kb and show that several cases of amplifications are compatible with a breakage-fusion-bridge mechanism. |
| Publication | Nature Communications |
| Volume | 7 |
| Pages | 12222 |
| Date | 07 13, 2016 |
| Journal Abbr | Nat Commun |
| Language | eng |
| DOI | 10.1038/ncomms12222 |
| ISSN | 2041-1723 |
| Library Catalog | PubMed |
| Extra | PMID: 27406316 PMCID: PMC4947184 |
| Tags | Breast Neoplasms, DNA Copy Number Variations, Estrogen Receptor alpha, Female, Gene Amplification, Gene Expression Profiling, Humans, Mutation, original, Polymorphism, Single Nucleotide, Receptor, ErbB-2, Receptors, Progesterone, Transcriptome, Whole Genome Sequencing |
| Date Added | 2018/11/13 - 17:26:07 |
| Date Modified | 2019/05/21 - 14:46:18 |
Institut de Recherche en Cancérologie de
